Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes.
People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.
An LSTM led partnership has been awarded nearly £1.5 million from the Medical Research Council for the pre-clinical development of a candidate drug to treat onchocerciasis and lymphatic filariasis, by targeting the bacterial symbiont Wolbachia.
To ensure elimination of the Wuchereria bancrofti, a parasitic roundworm that causes lymphatic filariasis, public health workers must follow up mass drug administration with careful monitoring for recurrence.
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide.
World Health Organization and Uniting to Combat NTDs collaborate to tackle the five most common Neglected tropical diseases; onchocerciasis, trachoma, schistosomiasis, lymphatic filariasis and helminthic infections.
Researchers from LSTM's Research Centre for Drugs and Diagnostics have found a way of significantly reducing the treatment required for lymphatic filariasis and onchocerciasis from several weeks to seven days. By targeting Wolbachia, a bacterial symbiont that the filarial parasites need to live, the team has discovered a drug synergy that enables effective treatment over a shorter time.
An estimated 120 million people worldwide are infected with lymphatic filariasis, a parasitic, mosquito-borne disease that can cause major swelling and deformity of the legs, a condition known as elephantiasis.
The World Health Organization’s Regional Director for Africa announced today four new flagship programs for the region over the next two years, including a major push on adolescent health and the creation of regional emergency hubs.
Since 2007, the World Health Organization (WHO) has been reporting outstanding success in dealing with neglected tropical diseases (NTDs) with 1 billion people estimated to have received treatments in 2015.
People infected with a parasitic worm called Wuchereria bancrofti in areas where HIV is endemic may be more likely to acquire HIV than people who are not infected with the worm, according to a new study in southwest Tanzania, published in The Lancet.
Since the start of the HIV epidemic, there have been speculations as to why HIV and the immunodeficiency syndrome it causes have spread so much more in Africa than in other countries around the world.
In rare instances, DNA is known to have jumped from one species to another. If a parasite's DNA jumps to its host's genome, it could leave evidence of that parasitic interaction that could be found millions of years later -- a DNA 'fossil' of sorts.
PATH and Standard Diagnostics/Alere announced today the commercial availability of two rapid diagnostic tools for onchocerciasis and lymphatic filariasis. Designed for use in disease surveillance, the antibody-based tests are part of a suite of diagnostic innovations intended to support the elimination of neglected tropical diseases (NTDs), a group of illnesses that affect more than a billion people worldwide.
Researchers at Washington University School of Medicine in St. Louis have received a $7 million grant from the Bill & Melinda Gates Foundation aimed at eliminating river blindness and elephantiasis, two neglected tropical diseases that annually sicken millions.
New Smartphone technology has been developed that can detect and count wriggling parasitic worms in a drop of blood...
WHO urges affected countries to scale up their investment in tackling 17 neglected tropical diseases in order to improve the health and well-being of more than 1.5 billion people. This investment would represent as little as 0.1% of current domestic expenditure on health in affected low and middle income countries for the period 2015-2030.
Liverpool School of Tropical Medicine is emerging high on the academic rankings under its own name following the designation of Higher Education Institutions status earlier in 2013.
The COUNTDOWN research consortium has been launched today following a £7 million grant allocation from the UK Department for International Development earlier in the year.
The Drugs for Neglected Diseases initiative has been awarded US$ 10 million by the United States Agency for International Development to develop new treatments for onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) - the first-ever USAID grant for neglected tropical disease research and development (R&D).
Celgene Global Health, a division of Celgene Corporation, and the Drugs for Neglected Diseases initiative strengthen their collaboration with a four-year Research Collaboration Agreement to identify and optimize new drug candidates for the treatment of neglected tropical diseases (NTDs).
Researchers are developing new drug treatments to tackle river blindness and elephantiasis, which affect up to 150 million people across the world.